Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 5/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5149907 | 0.79 | CA2 (0.52) | CA2CA1CA4CA7 | |
| SCHEMBL8122844 | 0.77 | ALDH1A1 (0.38) | GCKCA2 | |
| SCHEMBL5152395 | 0.67 | CCNE1 (0.38) | CA2CA1CA4CA7 | |
| SCHEMBL11056450 | 0.62 | — | — | |
| SCHEMBL28571882 | 0.62 | — | — | |
| SCHEMBL5156980 | 0.60 | GCK (0.36) | GCKCA2 | |
| SCHEMBL8021715 | 0.60 | LMNA (0.41) | CA2CA1CA4CA7 | |
| SCHEMBL23531742 | 0.59 | CA2 (0.50) | CA2CA1CA4CA7 | |
| SCHEMBL11306113 | 0.57 | MPL (0.33) | — | |
| SCHEMBL31618986 | 0.57 | CA1 (0.39) | CA2CA1CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288547-B2 | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2007-10-30 | — | — | US | disclosed |
| US-7288547-B2 | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2007-10-30 | — | — | US | disclosed |
| US-7288547-B2 | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2007-10-30 | — | — | US | disclosed |
| EP-1483260-A1 | CDK INHIBITING 2-HETEROARYL PYRIMIDINE, THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | Schering Aktiengesellschaft (DE) | 2004-12-08 | — | — | EP | disclosed |
| US-20040063737-A1 | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2004-04-01 | — | — | US | disclosed |
| WO-2003076437-A1 | CDK INHIBITING 2-HETEROARYL PYRIMIDINE, THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063737-A1 | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents | CDK2, CDK6, CDKL2 | GCK 376/4885CA2 3633/4885CA1 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.